Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of a New Probiotic Strain on Recurrent Acute Otitis Media in Children (PROMAR) (PROMAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03614117
Recruitment Status : Recruiting
First Posted : August 3, 2018
Last Update Posted : September 30, 2019
Sponsor:
Collaborator:
Casen Recordati S.L.
Information provided by (Responsible Party):
ProbiSearch SL

Brief Summary:
An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a new probiotic strain Lactobacillus salivarius PS7 on Acute Otitis Media (AOM) in children with recurrent AOM history. The study duration will be 7 months, which includes a 6-month product administration and a 1-month follow-up period. Participants will be randomized assigned to one of the three study groups: the control group; a 3 months probiotic +3 months placebo consumption group and a 6 months probiotic consumption group. The efficacy of the probiotic strain to reduce the incidence of AOM episodes will be assessed by counting AOM episodes occurring in study participants, during the entire intervention and follow-up periods, by bilateral comparison of each of the treatment groups with the control group according to the following hypothesis: "The number of AOM episodes occurring in participants who take the probiotic is the same as that for the participants in the control group. λc = λe". Where λc is the mean incidence of AOM in the control group and λe is the mean incidence of AOM in the groups taking the probiotic strain Lactobacillus salivarius PS7 obtained with 95% confidence interval.

Condition or disease Intervention/treatment Phase
Acute Otitis Media Dietary Supplement: Lactobacillus salivarius PS7 during 6 months Dietary Supplement: Lactobacillus salivarius PS7 during 3 months Dietary Supplement: placebo Not Applicable

Detailed Description:

The parent or legal guardian of the minors will be contacted during a visit to the pediatrician for suspected AOM to request their participation in the study, which will be voluntary.

The study visits will take place at the primary care center or hospital. During Visit 1, the inclusion and exclusion criteria will be verified, and the informed consent will be signed. Information will be collected on the demographic profile, characteristics of the AOM episode and the prescribed treatment; and the participants will be randomized. The investigator will give the parent or guardian the product corresponding to the first treatment period (3 months) and will explain how to administer it to the child, as well as when the next visits will take place and what they will entail. Instructions will be given to start the administration of the product as soon as possible after the collection of the first stool sample. A sample will be collected from the outer ear most affected by the AOM using a sterile swab (Day 0). The investigator will go over, with the parent or legal guardian, the details of the diary to be completed (Annex II), how to record the data on product administration, fever episodes, days of school or daycare missed, unscheduled visits to the pediatrician, as well as data related to the frequency and characteristics of the stools in the event of AOM episodes and/or antibiotic treatment. The investigator will inform the parent or legal guardian that, during the child's participation in the study, the child cannot take any probiotic supplement.

During Visit 2, a sample will be taken from the same ear as in the previous visit using a sterile swab. Any questions regarding completing the diary will be discussed. The leftover product from the first treatment period will be collected and the study product corresponding to the second supplement administration period will be dispensed.

At the third visit (Visit 3, after 6 months of product administration), a sample will be collected from the same ear as in previous visits using a sterile swab. Any leftover product from the second treatment period will be collected.

During the fourth visit (Visit 4, after 1 month of observation), a sample will be collected from the same ear as in previous visits using a sterile swab. The completed diary will be collected.

Throughout the duration of the child's participation in the study (7 months), additional visits to the pediatrician (study investigator) may take place. If an episode of AOM, otitis externa or respiratory tract infection occurs during the intervention period, the investigator will make a diagnosis and will start the necessary treatment. In the course of new AOM episodes, during the intervention period, the administration of the product will not be interrupted. If the AOM episode occurs during the observation period, the investigator will proceed according to his/her routine practice. At the additional visits taking place, relevant data will be collected on the possible Adverse Events (AEs) or Serious Adverse Events (SAEs), as well as on the concomitant medication.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is an interventional, randomized, double-blind, placebo-controlled, parallel-group study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of a Probiotic on Recurrent Acute Otitis Media (rAOM) in Children
Actual Study Start Date : October 2, 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ear Infections

Arm Intervention/treatment
Active Comparator: L.salivarius PS7 6-months
Lactobacillus salivarius PS7 during 6-months; approximately 1*10E9 colony forming unit (CFU) of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 6-months.
Dietary Supplement: Lactobacillus salivarius PS7 during 6 months
7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
Other Name: Lactobacillus salivarius CECT9422 during 6 months

Active Comparator: L. salivarius PS7 + placebo (3+3)
Lactobacillus salivarius PS7 during 3 months; approximately 1*10E9 CFU of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 3-months followed by 3 months oral administration of 1sachet per day of placebo supplement to be diluted in water.
Dietary Supplement: Lactobacillus salivarius PS7 during 3 months
7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
Other Name: Lactobacillus salivarius CECT9422 during 3 months

Placebo Comparator: Control group
Placebo supplement in 1 sachet per day to be diluted in water by mouth for 6-months.
Dietary Supplement: placebo
7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.




Primary Outcome Measures :
  1. Number of AOM episodes [ Time Frame: 7 months ]
    Number of AOM episodes suffered by participants


Secondary Outcome Measures :
  1. Patients (%) with at least one AOM episode during the intervention and follow-up periods. [ Time Frame: 7 months ]
    % of patients with at least one AOM episode

  2. Number of AOM episodes after 3 months of product intake. [ Time Frame: 3 months ]
    Number of AOM episodes suffered by participants after 3 months of product intake

  3. Time from onset of first AOM episode to the onset of the next episode. [ Time Frame: 7 months ]
    Number of days from onset of first AOM episode to the onset of the next episode.

  4. Adverse events and/or serious adverse events [ Time Frame: 7 months ]
    The number, duration and possible relationship of (serious) adverse events to the study product.


Other Outcome Measures:
  1. Variables assessing compliance with the protocol [ Time Frame: 7 months ]

    The variables assessing compliance with the protocol

    • Study product administration.
    • Probiotic supplement administration
    • Compliance with the visit/assessment intervals.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 4 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children 1 to 4 years of age with rAOM (3 episodes of AOM in the last 6 months, or 4 in the last 12 months).
  • Written informed consent signed by one of parents or legal guardian with the express or tacit consent of the other.
  • Presence of an AOM episode at the time of inclusion in the study.

Exclusion Criteria:

  • chronic conditions under regular medication, such as asthma, allergic rhinitis…
  • congenital or acquired immunodeficiency,
  • taking systemic corticoid in the last 3 months for longer than 1 month
  • under present prophylactic antibiotic treatment
  • Down syndrome,
  • cleft lip or palate,
  • chronic tympanic perforation,
  • craniofacial abnormalities,
  • sleep apnea syndrome,
  • planned tympanostomy or tonsillectomy during the months of the study,
  • short bowel syndrome or any surgery in the gastrointestinal tract,
  • intestinal epithelial barrier defect (e.g., chronic diarrhea, intestinal inflammation),
  • metabolic disorders (diabetes, etc.),
  • heart failure and cardiac medical history (e.g. artificial heart valve, medical history of infective endocarditis, rheumatic fever or cardiac malformation),
  • uncertainty of the investigator regarding the willingness or capacity of the parents or legal guardian of the child to comply with the requirements of the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03614117


Contacts
Layout table for location contacts
Contact: Susana Manzano, PhD +34 918 035 179 susana.manzano@probisearch.com
Contact: Esther A Jimenez, PhD +34 918 035 179 esther.jimenez@probisearch.com

Locations
Layout table for location information
Spain
Hospital Universitario QuirónSalud Pozuelo Recruiting
Pozuelo De Alarcón, Madrid, Spain, 28223
Contact: Javier Hernández Calvin, MD.         
Sponsors and Collaborators
ProbiSearch SL
Casen Recordati S.L.
Investigators
Layout table for investigator information
Study Chair: Susana Manzano, PhD ProbiSearch SL

Layout table for additonal information
Responsible Party: ProbiSearch SL
ClinicalTrials.gov Identifier: NCT03614117     History of Changes
Other Study ID Numbers: OTR/17.01
First Posted: August 3, 2018    Key Record Dates
Last Update Posted: September 30, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Otitis
Otitis Media
Ear Diseases
Otorhinolaryngologic Diseases